BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Piga M, Floris A, Sebastiani GD, Prevete I, Iannone F, Coladonato L, Govoni M, Bortoluzzi A, Mosca M, Tani C, Doria A, Iaccarino L, Franceschini F, Fredi M, Conti F, Spinelli FR, Galeazzi M, Bellisai F, Zanetti A, Carrara G, Scirè CA, Mathieu A. Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. Rheumatology (Oxford) 2020;59:2272-81. [PMID: 31840179 DOI: 10.1093/rheumatology/kez584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Cai T, Zhao J, Yang Y, Jiang Y, Zhang J. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. Lupus 2022. [DOI: 10.1177/09612033221129774] [Reference Citation Analysis]
2 Sebastiani GD, Mosca M, Ravasio R, Brambilla P, Raimondo P, Doria A. Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis. Grhta 2022;9:123-132. [DOI: 10.33393/grhta.2022.2470] [Reference Citation Analysis]
3 Rua-Figueroa Fernández de Larrinoa Í, Lozano MJC, Fernández-Cid CM, Cobo T, Salman Monte TC, Freire González M, Hidalgo Bermejo FJ, Román Gutiérrez CS, Cortés-Hernández J. Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. Expert Opin Biol Ther 2022;:1-9. [PMID: 35815355 DOI: 10.1080/14712598.2022.2096406] [Reference Citation Analysis]
4 Munroe ME, Young KA, Guthridge JM, Kamen DL, Gilkeson GS, Weisman MH, Ishimori ML, Wallace DJ, Karp DR, Harley JB, Norris JM, James JA. Pre-Clinical Autoimmunity in Lupus Relatives: Self-Reported Questionnaires and Immune Dysregulation Distinguish Relatives Who Develop Incomplete or Classified Lupus From Clinically Unaffected Relatives and Unaffected, Unrelated Individuals. Front Immunol 2022;13:866181. [DOI: 10.3389/fimmu.2022.866181] [Reference Citation Analysis]
5 Nakai T, Fukui S, Ikeda Y, Suda M, Tamaki H, Okada M. Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis. Lupus Sci Med 2022;9:e000682. [PMID: 35654482 DOI: 10.1136/lupus-2022-000682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kifer N, Sestan M, Frkovic M, Kifer D, Kozmar A, Padjen I, Potocki K, Anic B, Batinic D, Malcic I, Jelusic M. 2019 ACR/EULAR classification criteria and therapy in predicting organ damage accrual in patients with childhood-onset systemic lupus erythematosus: A retrospective study over the last 29 years. Lupus 2022;:9612033221094707. [PMID: 35410557 DOI: 10.1177/09612033221094707] [Reference Citation Analysis]
7 Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2110730. [DOI: 10.1177/1759720x211073001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kostopoulou M, Ugarte-Gil MF, Pons-Estel B, van Vollenhoven RF, Bertsias G. The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus. Lupus 2022;:9612033221074580. [PMID: 35067068 DOI: 10.1177/09612033221074580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Dima A, Jurcut C, Arnaud L. Hydroxychloroquine dans les maladies systémiques et auto-immunes : où en sommes-nous ? Revue du Rhumatisme 2021;88:346-353. [DOI: 10.1016/j.rhum.2021.05.002] [Reference Citation Analysis]
10 Piga M, Congia M, Balestrieri A, Angioni MM, Cangemi I, Cau R, Chessa E, Floris A, Figus F, Iagnocco A, Cauli A, Saba L. Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patients with Jaccoud's arthropathy and a distinctive MRI pattern. Rheumatology (Oxford) 2021;60:4218-28. [PMID: 33404658 DOI: 10.1093/rheumatology/keaa915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Adamichou C, Genitsaridi I, Nikolopoulos D, Nikoloudaki M, Repa A, Bortoluzzi A, Fanouriakis A, Sidiropoulos P, Boumpas DT, Bertsias GK. Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 2021:annrheumdis-2020-219069. [PMID: 33568388 DOI: 10.1136/annrheumdis-2020-219069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
12 Dima A, Jurcut C, Arnaud L. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now? Joint Bone Spine 2021;88:105143. [PMID: 33515791 DOI: 10.1016/j.jbspin.2021.105143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
13 Piga M, Arnaud L. The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? J Clin Med 2021;10:E243. [PMID: 33440874 DOI: 10.3390/jcm10020243] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]